약물 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 검체별, 약물별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Drug Testing Market Summary

The global drug testing market size was estimated at USD 7.09 billion in 2025 and is projected to reach USD 11.55 billion by 2033, growing at a CAGR of 6.32% from 2026 to 2033. The rising prevalence of substance abuse worldwide has increased the demand for testing solutions.

In addition, strict regulations from various government bodies requiring alcohol and substance testing for safety reasons, along with increased initiatives to monitor and address substance abuse, are anticipated to further enhance market growth.

The rising global rates of substance abuse have considerably increased the demand for testing solutions. According to the Substance Abuse and Mental Health Services Administration (SAMHSA) 2024 National Survey on Drug Use and Health, about 73.6 million Americans aged 12 or older (25.5%) reported using illicit drugs in the past year. Cannabis remains the most commonly used illicit drug, with around 64.2 million users, followed by substances such as hallucinogens, prescription opioids, and cocaine. The ongoing opioid crisis has also increased the need for monitoring and testing programs across healthcare, workplace, and law enforcement sectors. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded over 107,000 drug overdose deaths in 2023, highlighting the serious public health impact of drug misuse. These rising cases of substance misuse and overdose are encouraging governments, employers, and healthcare providers to adopt regular drug screening and monitoring programs, which is supporting the growth of the U.S. drug testing industry.

Moreover, the alarming rise in alcohol and substance-related deaths emphasizes the urgent need for reliable testing solutions, driving demand for innovative technologies and services to support substance abuse detection, treatment, and prevention efforts in healthcare and public safety sectors. In June 2024, WHO report shows that over 3 million annual deaths are linked to alcohol and substance use, predominantly affecting men. Of these, 2.6 million deaths are due to alcohol, while 0.6 million are attributed to psychoactive drugs. The report highlights that around 400 million people suffer from alcohol use disorders globally, with 209 million experiencing dependence. Despite some declines in alcohol-related death rates, the overall figures remain alarmingly high, especially in low-income countries. The report calls for urgent actions to reduce alcohol and drug consumption and improve access to treatment, emphasizing the need for a coordinated global advocacy campaign and enhanced treatment capabilities in healthcare systems to achieve Sustainable Development Goal 3.5 by 2033.

Increased resources for treatment programs may lead to a higher demand for testing services to monitor compliance and effectiveness of treatments. The emphasis on addressing substance use disorders, especially among underserved populations, can spur innovations in technologies and methodologies. Furthermore, with comprehensive opioid recovery initiatives, there may be a greater need for accurate screening to prevent misuse, ultimately supporting growth in the market. In July 2024, The Biden-Harris Administration has awarded USD 45.1 million to expand services for substance use disorders. Key initiatives include USD 7.5 million for homeless individuals with substance use disorders, USD 4 million for minorities at high risk for HIV/AIDS, and USD 1.7 million for comprehensive opioid recovery centers.

Global Drug Testing Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug testing market report based on product, sample, drug, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments
• Rapid Testing Devices
• Services
• Sample Outlook (Revenue, USD Million, 2021 - 2033)
• Urine Samples
• Oral Fluid Samples
• Hair Samples
• Other Samples
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Testing Laboratories
• Workplaces
• Hospitals
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Sample
  • 1.2.3. Drug
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Sample outlook
  • 2.2.3. Drug outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Drug Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of substance abuse
    • 3.2.1.2. Stringent laws mandating alcohol and drug testing
    • 3.2.1.3. Increasing government initiatives to monitor substance abuse
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Drug testing is considered a violation of privacy rights in some countries
• 3.3. Drug Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Drug Testing Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Drug Testing Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Consumables
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Rapid Testing Devices
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Services
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Drug Testing Market: Sample Estimates & Trend Analysis

• 5.1. Sample Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Drug Testing Market by Sample Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Urine samples
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Oral fluid samples
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Hair samples
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. Other Samples
    • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Drug Testing Market: Drug Estimates & Trend Analysis

• 6.1. Drug Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Drug Testing Market by Drug Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Alcohol
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 6.4.2. Cannabis/Marijuana
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Cocaine
    • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Opioids
    • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Amphetamine & Methamphetamine
    • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. LSD
    • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.7. Others
    • 6.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Drug Testing Market: End use Estimates & Trend Analysis

• 7.1. Ens Use Market Share, 2025 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Drug Testing Market by End Use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.4.1. Drug Testing Laboratories
    • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 7.4.2. Workplaces
    • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Hospitals
    • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Drug Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2025
  • 9.3.4. Quest Diagnostics Incorporated
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Abbott
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. F. Hoffmann-La Roche Ltd.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Quidel Corporation
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Thermo Fisher Scientific, Inc
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Siemens Healthcare GmbH
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Bio-Rad Laboratories, Inc.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Agilent Technologies, Inc.
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Laboratory Corporation of America Holdings
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Clinical Reference Laboratory, Inc.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Cordant Health Solutions
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives